Are You Targeting Non-High-Density Lipoprotein Cholesterol?

Journal of the American College of Cardiology

Volumn 55, Issue 1, 2009, Pages 42-44

  Robinson, Jennifer G ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

coronary heart disease risk; low density lipoprotein cholesterol; non high density lipoprotein cholesterol; total cholesterol high density lipoprotein cholesterol ratio; triglycerides

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHYLOMICRON; CHYLOMICRON REMNANT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; EDITORIAL; FOLLOW UP; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMOBILIZATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; OBESITY; PRIORITY JOURNAL; SMOKING;

CHOLESTEROL; CORONARY DISEASE; HUMANS; RISK FACTORS; TRIGLYCERIDES;

EID: 72549104133     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.07.056     Document Type: Editorial

References (16)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
2. Miller M., Ginsberg H.N., and Schaefer E.J. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 101 (2008) 1003-1008
3. Arsenault B.J., Rana J.S., Stroes E.S.G., et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 55 (2010) 35-41
4. Sarwar N., Danesh J., Eiriksdottir G., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115 (2007) 450-458
5. Miller M., Cannon C.P., Murphy S.A., Qin J., Ray K.K., and Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51 (2008) 724-730
6. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., and Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298 (2007) 309-316
7. Robinson J.G., Wang S., Smith B.J., and Jacobson T.A. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 53 (2009) 316-322
8. Kastelein J.J.P., van der Stieg W., Holme I., et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117 (2008) 3002-3009
9. Briel M., Ferreira-Gonzalez I., You J.J., et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338 (2009) b92
10. Ginsberg H.N., Bonds D.E., Lovato L.C., et al., ACCORD Study Group. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99 (2007) S56-S67
11. AIM-HIGH: Niacin plus statin to prevent vascular events. (NCT00120289) (2006), National Heart Lung and Blood Institute. http://www.clinicaltrials.gov/show/NCT00120289 Available at: http://www.clinicaltrials.gov/show/NCT00120289. Accessed November 21, 2006
12. Mozaffarian D., Wilson P.W.F., and Kannel W.B. Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease. Circulation 117 (2008) 3031-3038
13. Robinson J.G., and Stone N.J. Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am J Cardiol 98 (2006) 1405-1408
14. Sniderman A.D. The case against ApoB and the ApoB:ApoA-I ratio: are they right?. Future Lipidol 3 (2008) 257-264
15. Blaha M., Blumenthal R., Brinton E., Jacobson T., and National Lipid Association Taskforce on Non-HDL Cholesterol. The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol 2 (2008) 267-273
16. Ballantyne C.M., Raichlen J.S., and Cain V.A. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) trial. J Am Coll Cardiol 52 (2008) 626-632